Medtronic Receives CE Mark Approval for SenSight™ Directional Lead System for DBS Therapy globalbankingandfinance.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globalbankingandfinance.com Daily Mail and Mail on Sunday newspapers.
Vice President, Head of Investor Relations
Good morning and welcome to Medtronic s Fiscal Year 2021 Third Quarter Earnings Video Webcast. I m Ryan Weispfenning, Vice President and Head of Medtronic Investor Relations.
Before we start the prepared remarks, I m going to share with you a few details to keep in mind about today s webcast. Joining me today are Geoff Martha, Medtronic Chairman and Chief Executive Officer; and Karen Parkhill, Medtronic Chief Financial Officer. Geoff and Karen will provide comments on the results of our third quarter, which ended on January 29, 2021. After our prepared remarks, we ll take questions from the sell-side analysts that cover the Company, and today s event should last about an hour.
BPH Energy Limited (ASX:BPH) Cortical Dynamics Patent and Advisory Panel Appoint Update
Cortical Dynamics Patent and Advisory Panel Appoint UpdatePerth, Jan 22, 2021 AEST (ABN Newswire) - BPH Energy Ltd (
ASX:BPH) investee company Cortical Dynamics Ltd ( Cortical ) is pleased to announce the issuance of European Patent Number 2088924 Neurodiagnostic Monitoring and display System in Belgium, France, Germany and United Kingdom.
Cortical has developed an extensive patent portfolio encapsulating the BARM, providing critical patent protection across a number of key brain monitoring markets.
Corticals competitive advantage is underpinned by a strong patent position covered by six patent families and 26 granted patents.
Currently, Cortical has patents awarded in Australia, New Zealand, Japan, the People s Republic of China, Europe and the United States.
Medtronic unveils adaptive deep brain stimulation trial in Parkinson s patients
Medtronic unveils adaptive deep brain stimulation trial in Parkinson s patients
15 January 2021 | News The randomised study will take place across 12 study sites at leading movement disorders research centers in the US, Europe, and Canada
Source: medtronic.com
Medtronic plc, the global leader in medical technology, announced the first enrolment in ADAPT-PD (Adaptive DBS Algorithm for Personalised Therapy in Parkinson s Disease), its trial evaluating the safety and efficacy of adaptive deep brain stimulation (aDBS) in patients with Parkinson s Disease (PD). Adaptive deep brain stimulation is an investigational feature of the Percept™ PC device that could be enabled if approved.
Medtronic said the ADAPT-PD study will look at the safety and efficacy of the use of adaptive deep brain stimulation in patients with Parkinson’s Disease.